Literature DB >> 35927363

White adipose tissue-derived factors and prostate cancer progression: mechanisms and targets for interventions.

Achinto Saha1,2,3, Jill Hamilton-Reeves4, John DiGiovanni5,6,7,8.   

Abstract

Obesity represents an important risk factor for prostate cancer, driving more aggressive disease, chemoresistance, and increased mortality. White adipose tissue (WAT) overgrowth in obesity is central to the mechanisms that lead to these clinical observations. Adipose stromal cells (ASCs), the progenitors to mature adipocytes and other cell types in WAT, play a vital role in driving PCa aggressiveness. ASCs produce numerous factors, especially chemokines, including the chemokine CXCL12, which is involved in driving EMT and chemoresistance in PCa. A greater understanding of the impact of WAT in obesity-induced progression of PCa and the underlying mechanisms has begun to provide opportunities for developing interventional strategies for preventing or offsetting these critical events. These include weight loss regimens, therapeutic targeting of ASCs, use of calorie restriction mimetic compounds, and combinations of compounds as well as specific receptor targeting strategies.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Adipose tissue; Chemokines; Obesity; Prostate cancer

Mesh:

Substances:

Year:  2022        PMID: 35927363      PMCID: PMC9474694          DOI: 10.1007/s10555-022-10056-0

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.237


  292 in total

Review 1.  Body size and prostate cancer.

Authors:  A M Nomura
Journal:  Epidemiol Rev       Date:  2001       Impact factor: 6.222

Review 2.  Interleukin-8: a review.

Authors:  C A Hébert; J B Baker
Journal:  Cancer Invest       Date:  1993       Impact factor: 2.176

3.  Vigorous Physical Activity Is Associated with Lower Risk of Metastatic-Lethal Progression in Prostate Cancer and Hypomethylation in the CRACR2A Gene.

Authors:  James Y Dai; Bo Wang; Xiaoyu Wang; Anqi Cheng; Suzanne Kolb; Janet L Stanford; Jonathan L Wright
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-11-21       Impact factor: 4.254

4.  CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration.

Authors:  Robert D Loberg; Chi Ying; Matt Craig; Li Yan; Linda A Snyder; Kenneth J Pienta
Journal:  Neoplasia       Date:  2007-07       Impact factor: 5.715

5.  Infiltrating macrophages promote prostate tumorigenesis via modulating androgen receptor-mediated CCL4-STAT3 signaling.

Authors:  Lei-Ya Fang; Kouji Izumi; Kuo-Pao Lai; Liang Liang; Lei Li; Hiroshi Miyamoto; Wen-Jye Lin; Chawnshang Chang
Journal:  Cancer Res       Date:  2013-07-22       Impact factor: 12.701

6.  CXCL5 promotes prostate cancer progression.

Authors:  Lesa A Begley; Sathish Kasina; Rohit Mehra; Shreelekha Adsule; Andrew J Admon; Robert J Lonigro; Arul M Chinnaiyan; Jill A Macoska
Journal:  Neoplasia       Date:  2008-03       Impact factor: 5.715

7.  A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1)

Authors:  C C Bleul; R C Fuhlbrigge; J M Casasnovas; A Aiuti; T A Springer
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

Review 8.  Bone Marrow Adipose Tissue: A New Player in Cancer Metastasis to Bone.

Authors:  Emma V Morris; Claire M Edwards
Journal:  Front Endocrinol (Lausanne)       Date:  2016-07-14       Impact factor: 5.555

9.  CCL7 Is a Negative Regulator of Cutaneous Inflammation Following Leishmania major Infection.

Authors:  Jill Ford; Angela Hughson; Kihong Lim; Susana V Bardina; Wuyuan Lu; Israel F Charo; Jean K Lim; Deborah J Fowell
Journal:  Front Immunol       Date:  2019-01-08       Impact factor: 7.561

10.  Intermittent energy restriction induces changes in breast gene expression and systemic metabolism.

Authors:  Michelle N Harvie; Andrew H Sims; Mary Pegington; Katherine Spence; Adam Mitchell; Andrew A Vaughan; J William Allwood; Yun Xu; Nicolas J W Rattray; Royston Goodacre; D Gareth R Evans; Ellen Mitchell; Debbie McMullen; Robert B Clarke; Anthony Howell
Journal:  Breast Cancer Res       Date:  2016-05-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.